US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Neo-Concept International Group Holdings Limited

0.3950

-0.0449-10.21%

Volume:35.77K

Turnover:14.47K

Market Cap:8.03M

PE:5.17

High:0.4100

Open:0.4099

Low:0.3903

Close:0.4399

Loading ...

Overview Company News Filings

AECOM reports first quarter fiscal 2025 results

Fusion Antibodies Advances OptiMAL® Project with NCI Collaboration

Shell announces commencement of a share buyback programme

Press Release: Shell plc Fourth Quarter 2024 Interim Dividend

Shell plc publishes fourth quarter 2024 press release

CBA shares pushes higher on $940m deal

Press Release: Shell completes acquisition of combined-cycle power plant in priority U.S. trading market

Shell plc announces changes to the Executive Committee

Kinder Morgan Reports Fourth Quarter 2024 Financial Results

Press Release: Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025

BRIEF-NCI Granted Second Grace Period By Nasdaq For Minimum Bid Price Compliance

Nci Granted Second Grace Period by Nasdaq for Minimum Bid Price Compliance

THOMSON REUTERS

NCI Granted Second Grace Period by Nasdaq for Minimum Bid Price Compliance

SELLAS Announces Key Business Objectives for 2025

Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287

Shell fourth quarter 2024 update note

Guardant Health Shield test selected for use in NCI Vanguard study

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial

Neo-Concept International Group Holdings First Half 2024 Earnings: EPS: HK$0.075 (vs HK$0.29 loss in 1H 2023)

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NCI/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NCI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","market":"US","secType":"STK","nameCN":"Neo-Concept International Group Holdings Limited","latestPrice":0.395,"timestamp":1745265600000,"preClose":0.4399,"halted":0,"volume":35765,"delay":0,"floatShares":1726200,"shares":20320000,"eps":0.076408,"marketStatus":"Pre-Mkt","change":-0.0449,"latestTime":"04-22 07:29:20 EDT","open":0.4099,"high":0.41,"low":0.3903,"amount":14473.787921,"amplitude":0.044783,"askPrice":0.6318,"askSize":200,"bidPrice":0.2749,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.076408,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745328600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1713844800000,"exchange":"NASDAQ","adjPreClose":0.3949,"dividendRate":0.506329,"postHourTrading":{"tag":"盘后","latestPrice":0.4,"preClose":0.395,"latestTime":"18:47 EDT","volume":1903,"amount":772,"timestamp":1745275632084},"volumeRatio":0.36100671978680415},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","floatShares":1726200,"roa":"6.28%","roe":"58.31%","lyrEps":0.031396,"volumeRatio":0.36100671978680415,"shares":20320000,"dividePrice":0.2,"high":0.41,"amplitude":0.044783,"preClose":0.4399,"low":0.3903,"week52Low":0.3501,"pbRate":"1.25","psRate":"0.35","week52High":11.39,"institutionHeld":0.7857,"latestPrice":0.395,"committee":-0.333333,"eps":0.076408,"divideRate":0.506329,"volume":35765,"delay":0,"ttmEps":0.076408,"open":0.4099,"prevYearClose":0.66,"prevWeekClose":0.4399,"prevMonthClose":0.48,"prevQuarterClose":0.48,"fiveDayClose":0.43,"twentyDayClose":0.4159,"sixtyDayClose":0.68},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NCI\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2508173029","title":"AECOM reports first quarter fiscal 2025 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2508173029","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508173029?lang=en_us&edition=fundamental","pubTime":"2025-02-04 05:05","pubTimestamp":1738616700,"startTime":"0","endTime":"0","summary":"Delivered strong performance on all key financial metrics. Achieved the 17th consecutive quarter with a greater than 1.0x book-to-burn ratio, driven by a 1.2x book-to-burn in the design business; backlog and pipeline are at all-time highs. DALLAS, February 03, 2025----AECOM , the trusted global infrastructure leader, today reported first quarter fiscal 2025 results.\"We are off to a strong start in fiscal 2025 with first quarter results that exceeded our expectations,\" said Gaurav Kapoor, AECOM’s chief financial and operations officer. \"This includes accelerating NSR growth, record first quarter margins and double-digit adjusted EPS growth. As we look ahead, continued expected growth and the high return on our strategic investments underpin our confidence in delivering a 17% margin exit rate by the end of fiscal 2026 and even higher margins over time. Importantly, our balance sheet remains strong and we delivered a 28% increase in free cash flow, which supported continued returns of cap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aecom-reports-first-quarter-fiscal-210500711.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4129","BK4202","LU2308191902.HKD","NCI","NSR","BK4516","ACM"],"gpt_icon":0},{"id":"2507939765","title":"Fusion Antibodies Advances OptiMAL® Project with NCI Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2507939765","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507939765?lang=en_us&edition=fundamental","pubTime":"2025-01-31 15:24","pubTimestamp":1738308265,"startTime":"0","endTime":"0","summary":"Fusion Antibodies Plc ( ($GB:FAB) ) just unveiled an update. Fusion Antibodies plc announced progress in its OptiMAL® validation project in collabo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fusion-antibodies-advances-optimal-project-with-nci-collaboration?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fusion-antibodies-advances-optimal-project-with-nci-collaboration?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NCI","BK4202"],"gpt_icon":0},{"id":"2507619265","title":"Shell announces commencement of a share buyback programme","url":"https://stock-news.laohu8.com/highlight/detail?id=2507619265","media":"GlobeNewswire","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507619265?lang=en_us&edition=fundamental","pubTime":"2025-01-30 15:03","pubTimestamp":1738220580,"startTime":"0","endTime":"0","summary":"Shell plc Shell announces commencement of a share buyback programme  January 30, 2025 Shell plc (the ‘Company’) today announces the commencement of a $3.5 billion share buyback programme covering an a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/30/3017733/0/en/Shell-announces-commencement-of-a-share-buyback-programme.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4156","BK4202","NCI"],"gpt_icon":0},{"id":"2507619073","title":"Press Release: Shell plc Fourth Quarter 2024 Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2507619073","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507619073?lang=en_us&edition=fundamental","pubTime":"2025-01-30 15:02","pubTimestamp":1738220520,"startTime":"0","endTime":"0","summary":"London, January 30, 2025 - The Board of Shell plc   today announced an interim dividend in respect of the fourth quarter of 2024 of US$ 0.358 per ordinary share.Details relating to the fourth quarter 2024 interim dividend. Shareholders will be able to elect to receive their dividends in US dollars, euros or pounds sterling.Absent any valid election to the contrary, persons holding their ordinary shares through Euroclear Nederland will receive their dividends in euros.Absent any valid election to the contrary, shareholders  and persons holding their shares through the Shell Corporate Nominee will receive their dividends in pounds sterling.Each ADS represents two ordinary shares. ADSs are evidenced by an American Depositary Receipt  certificate. In many cases the terms ADR and ADS are used interchangeably.Dividend timetable for the fourth quarter 2024 interim dividend. The following organisations offer Dividend Reinvestment Plans  which enable the Company's shareholders to elect to have ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0278409577.USD","LU2236285917.USD","LU0300736062.USD","BK4201","BK4202","LU0320765646.SGD","SHEL","LU1162221912.USD","NCI","LU0300736492.USD","LU0098860793.USD","BK4588"],"gpt_icon":0},{"id":"2507619258","title":"Shell plc publishes fourth quarter 2024 press release","url":"https://stock-news.laohu8.com/highlight/detail?id=2507619258","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507619258?lang=en_us&edition=fundamental","pubTime":"2025-01-30 15:01","pubTimestamp":1738220460,"startTime":"0","endTime":"0","summary":"London, January 30, 2025 \"2024 was another year of strong financial performance across Shell. Despite the lower earnings this quarter, cash delivery remained solid and we generated free cash flow of $","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/30/3017731/0/en/Shell-plc-publishes-fourth-quarter-2024-press-release.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4561","NCI","BK4006","MT","BK4202"],"gpt_icon":0},{"id":"2506208534","title":"CBA shares pushes higher on $940m deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2506208534","media":"MotleyFool","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506208534?lang=en_us&edition=fundamental","pubTime":"2025-01-28 07:22","pubTimestamp":1738020164,"startTime":"0","endTime":"0","summary":"Commonwealth Bank of Australia  shares are on the move on Tuesday morning. At the time of writing, the banking giant's shares are up 1% to $159.95. Why are CBA shares rising?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/28/cba-shares-pushes-higher-on-940m-deal/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7135","XJO.AU","BK4202","XAO.AU","NCI","CBA.AU","XKO.AU","CBA"],"gpt_icon":0},{"id":"2505696968","title":"Press Release: Shell completes acquisition of combined-cycle power plant in priority U.S. trading market","url":"https://stock-news.laohu8.com/highlight/detail?id=2505696968","media":"Dow Jones","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505696968?lang=en_us&edition=fundamental","pubTime":"2025-01-24 22:30","pubTimestamp":1737729000,"startTime":"0","endTime":"0","summary":"HOUSTON, Jan. 24, 2025 /PRNewswire/ -- Shell Energy North America ,L.P. , a subsidiary of Shell plc , has completed the. previously announced 100% equity stake acquisition of RISEC Holdings,LLC , which owns a 609-megawatt  two-unit combined-cycle gas. This acquisition maintains SENA's position in the deregulated. securing long-term supply and capacity offtake for Shell. In the coming. decades, power demand is expected to increase in the ISO New England. market due to growing decarbonization efforts in sectors such as home. The acquisition has been absorbed within Shell's cash capital. -- This acquisition allows Shell to continue an energy supply agreement that. has been in place since 2019 and secure long-term energy offtake from the. The acquisition preserves SENA's current operations and mitigates market. risk by ensuring a reliable and stable power generation source.-- RISEC's two-unit combined-cycle gas turbine power plant has a maximum. the ISO New England market, the plant is loc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SHEL","BK4202","NCI","LU0320765646.SGD","BK6500","LU1162221912.USD","LU0300736492.USD","LU0300736062.USD","LU2236285917.USD","LU0098860793.USD","5QT.SI","BK4585","BK4201","LU0278409577.USD"],"gpt_icon":0},{"id":"2505054862","title":"Shell plc announces changes to the Executive Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2505054862","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505054862?lang=en_us&edition=fundamental","pubTime":"2025-01-23 15:00","pubTimestamp":1737615600,"startTime":"0","endTime":"0","summary":"London, January 23, 2025  Huibert Vigeveno, Downstream, Renewables and Energy Solutions Director, and a member of the Executive Committee since 1 January 2020, will step down after 30 years of distinguished service, effective 31 March 2025, to pursue other opportunities.Wael Sawan, Chief Executive Officer, said: “I am grateful to Huibert for his outstanding contributions to Shell, driving our customer value proposition across a range of businesses and geographies, successfully leading the BG integration, and most importantly, for leading the transformation in Downstream, Renewables and Energy Solutions, through a disciplined focus on performance, portfolio and people. Today’s performance is testament to his leadership, and he leaves Downstream, Renewables and Energy Solutions strongly positioned for the future. I wish him well in his future endeavours.”Andrew Smith will be appointed Director, Trading and Supply, and Machteld de Haan will be appointed Director, Downstream, Renewables an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shell-plc-announces-changes-executive-070000279.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4201","LU0300736062.USD","LU0320765646.SGD","NCI","BK4202","SHEL","LU1162221912.USD","BK4585","LU0278409577.USD","LU2236285917.USD","BK4588","LU0098860793.USD","LU0300736492.USD"],"gpt_icon":0},{"id":"2505706024","title":"Kinder Morgan Reports Fourth Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2505706024","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505706024?lang=en_us&edition=fundamental","pubTime":"2025-01-23 05:05","pubTimestamp":1737579900,"startTime":"0","endTime":"0","summary":"Earnings per Share  up 11% and Adjusted EPS up 14%. HOUSTON, January 22, 2025----Kinder Morgan, Inc.’s  board of directors today approved a cash dividend of $0.2875 per share for the fourth quarter , payable on February 18, 2025, to stockholders of record as of the close of business on February 3, 2025. This dividend is a 2% increase over the fourth quarter of 2023.Fourth quarter earnings per share  of $0.30, up 11% compared to the fourth quarter of 2023 and Adjusted EPS of $0.32, up 14% compared to the fourth quarter of 2023.Adjusted EBITDA of $2,063 million, up 7% versus the fourth quarter of 2023.\"For several quarters now, we have pointed to expected significant new natural gas demand for LNG, power plants, and emerging opportunities such as artificial intelligence operations, cryptocurrency mining, data centers and industrial re-shoring. These expectations are being realized. Our commercial teams have secured contracts to underpin three large natural gas projects - South System Exp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kinder-morgan-reports-fourth-quarter-210500927.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0320765646.SGD","BK4551","LU0251143029.SGD","LU0210637038.USD","LU0979878070.USD","LU2028103732.USD","LU1732800096.USD","FCF","NCI","LU0098860793.USD","BK4211","LU1242518857.USD","LU0225283273.USD","LU1363072403.SGD","LU2023251221.USD","LU1720051017.SGD","LU0516423174.USD","LU0264606111.USD","IE00BZ1G4Q59.USD","IE00B2Q91V27.USD","WTI","SG9999002604.SGD","LU0971096721.USD","LU2089283258.USD","BK4504","LU2125910500.SGD","LU2133065610.SGD","LU1989772840.SGD","DCF","LU0106831901.USD","LU0795875086.SGD","LU1548497426.USD","SG9999013478.USD","LU1732799900.SGD","LU2271345857.HKD","KMI","SG9999014484.SGD","SG9999004360.SGD","LU1668664300.SGD","TGP","LU2347655156.SGD","LU0572940350.SGD","BK4085","LU0516422366.SGD","LU0158827948.USD","LU0532188223.SGD","BK4127","LU1162221912.USD"],"gpt_icon":1},{"id":"2503949583","title":"Press Release: Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503949583","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503949583?lang=en_us&edition=fundamental","pubTime":"2025-01-13 05:00","pubTimestamp":1736715600,"startTime":"0","endTime":"0","summary":"Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025. -- Cabozantinib franchise achieves approximately $1.805 billion in preliminary U.S. net product revenues for fiscal year 2024 --. -- Fiscal year 2025 net product revenues guidance of $1.95 billion - $2.05 billion --. -- Presentation and webcast at 43 Annual J.P. Morgan Healthcare Conference tomorrow, Monday, January 13 at 5:15 p.m. PT / 8:15 p.m. ET --. Preliminary Fiscal Year 2024 Financial Results & 2025 Financial Guidance. Exelixis is providing the following preliminary unaudited 2024 financial results and financial guidance for 2025. Net product and total revenues guidance do not currently reflect any revenues resulting from a potential U.S. regulatory approval and commercial launch of CABOMETYX  for the treatment of patients with previously treated advanced neuroendocrine tumors . The U.S. Food and Drug Administration  is currentl","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4554","BK4022","R","NET","BK4116","BK4139","BK4213","BK4548","CRC","LU0456854461.SGD","BK4588","OS","BK4585","BK4195","BK4097","BK4532","LU2286300806.USD","BK4232","NCI","LU0266512127.USD","BK4211","PFS","EXEL","BK4560","BK4202"],"gpt_icon":0},{"id":"2501787147","title":"BRIEF-NCI Granted Second Grace Period By Nasdaq For Minimum Bid Price Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2501787147","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501787147?lang=en_us&edition=fundamental","pubTime":"2025-01-08 22:33","pubTimestamp":1736346791,"startTime":"0","endTime":"0","summary":"Jan 8 (Reuters) - Neo-Concept International Group Holdings Ltd   :   * NCI GRANTED SECOND GRACE PERIOD BY NASDAQ FOR MINIMUM BID PRICE COMPLIANCESource text:   Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4202","PSQ","TQQQ","MNQmain","LU2095319765.USD","LU2210150020.SGD","NVIW.SI",".IXIC","TSYW.SI","IE00BGHQF748.EUR","BK4588","SQQQ","USJW.SI","NQmain","BK4585","IE00BKPKM429.USD","NCI","BK4112","QID","LU2210149790.SGD","IE00B64PRP62.GBP","USAW.SI","NDAQ","QLD"],"gpt_icon":0},{"id":"2501662720","title":"Nci Granted Second Grace Period by Nasdaq for Minimum Bid Price Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2501662720","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501662720?lang=en_us&edition=fundamental","pubTime":"2025-01-08 22:02","pubTimestamp":1736344934,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nFWN3O40TS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4202","NCI"],"gpt_icon":0},{"id":"2501372024","title":"NCI Granted Second Grace Period by Nasdaq for Minimum Bid Price Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2501372024","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501372024?lang=en_us&edition=fundamental","pubTime":"2025-01-08 22:00","pubTimestamp":1736344800,"startTime":"0","endTime":"0","summary":"HONG KONG, Jan.  08, 2025  (GLOBE NEWSWIRE) --  Neo-Concept International Group Holdings Limited (Nasdaq: NCI) (the “Company”) announced that it received a letter from Nasdaq on January 7, 2025, indic","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/08/3006306/0/en/NCI-Granted-Second-Grace-Period-by-Nasdaq-for-Minimum-Bid-Price-Compliance.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1184","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK1550","BK4202","NCI","TSYW.SI","BK4588","USJW.SI","BK4112","MNQmain","TQQQ","BK1584","IE00B3QW5Z07.USD","QID",".IXIC","NQmain","NDAQ","SQQQ","BK4585","QLD","LU2095319765.USD","NVIW.SI","LU2210150020.SGD","IE00BKPKM429.USD","PSQ","LU2210149790.SGD","USAW.SI","01336"],"gpt_icon":1},{"id":"2501772285","title":"SELLAS Announces Key Business Objectives for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501772285","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501772285?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:20","pubTimestamp":1736342400,"startTime":"0","endTime":"0","summary":"- Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 - - SLS009: Full Topline Phase 2 Data in Acute Myeloid Leukemia and FDA Regulatory Review Exp","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/08/3006252/0/en/SELLAS-Announces-Key-Business-Objectives-for-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALL","LU2355687059.USD","ASH","BK4107","SLS","INN","LU1699723380.USD","BK4202","LU0985320562.USD","LU1571399168.USD","BK4183","BK4533","LU2463526074.USD","NCI","BK4218","ODD","BK4181","BK4585","BK4588","BK4109"],"gpt_icon":0},{"id":"2501272170","title":"Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287","url":"https://stock-news.laohu8.com/highlight/detail?id=2501272170","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501272170?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:00","pubTimestamp":1736341200,"startTime":"0","endTime":"0","summary":"BETHESDA, Md., Jan. 08, 2025  -- Gain Therapeutics, Inc.  , a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the formation of its Clinical Advisory Board  to support the continued development of the Company’s lead drug candidate, GT-02287, in Parkinson’s disease. The CAB is composed of leading experts in Parkinson’s disease trial design, genetics, and biomarkers and will work closely with Gain leadership to progress GT-02287 through potential Phase 2 and Phase 3 clinical development.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gain-therapeutics-announces-formation-clinical-130000745.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NCI","BK4119","PD","BK4202","GANX","LU1169590202.USD","BK4139","GT","BK4588","LENZ","BK4023","BK4585","CAB","LU1169589451.USD"],"gpt_icon":0},{"id":"2501159367","title":"Shell fourth quarter 2024 update note","url":"https://stock-news.laohu8.com/highlight/detail?id=2501159367","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501159367?lang=en_us&edition=fundamental","pubTime":"2025-01-08 15:00","pubTimestamp":1736319600,"startTime":"0","endTime":"0","summary":"The following is an update to the fourth quarter 2024 outlook and gives an overview of our current expectations for the fourth quarter. Outlooks presented may vary from the actual fourth quarter 2024 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/08/3005966/0/en/Shell-fourth-quarter-2024-update-note.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4561","MT","BK4202","NCI"],"gpt_icon":0},{"id":"2501206734","title":"Guardant Health Shield test selected for use in NCI Vanguard study","url":"https://stock-news.laohu8.com/highlight/detail?id=2501206734","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501206734?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:10","pubTimestamp":1736255443,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced the National Cancer Institute, or NCI, has selected the company’s Shield multi-cancer detection test for use in its ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-shield-test-selected-for-use-in-nci-vanguard-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-shield-test-selected-for-use-in-nci-vanguard-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GH","BK4585","NCI","BK4551","BK4588","BK4202","BK4535","BK4196"],"gpt_icon":0},{"id":"2501206969","title":"MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay","url":"https://stock-news.laohu8.com/highlight/detail?id=2501206969","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501206969?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:00","pubTimestamp":1736254800,"startTime":"0","endTime":"0","summary":"HOUSTON and SALT LAKE CITY, Jan.  07, 2025  (GLOBE NEWSWIRE) -- The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/07/3005354/15459/en/MD-Anderson-and-Myriad-Genetics-form-strategic-alliance-to-evaluate-clinical-utility-of-Myriad-s-molecular-residual-disease-assay.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4202","NCI","BK4139","MYGN","MD","BK4196"],"gpt_icon":0},{"id":"2501247267","title":"BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2501247267","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501247267?lang=en_us&edition=fundamental","pubTime":"2025-01-07 14:26","pubTimestamp":1736231160,"startTime":"0","endTime":"0","summary":"BERGEN, Norway, Jan. 7, 2025 /PRNewswire/ --BerGenBio ASA , a clinical-stage biopharmaceutical company developing the novel, selective AXL kinase inhibitor bemcentinib for lung cancer announced today that the first patient has been included in a clinical trial sponsored by the Mays Cancer Center at The University of Texas Health Science Center at San Antonio . The study is led by Josephine A. Taverna, MD, a thoracic oncologist at the Mays Cancer Center and Associate Professor in the Division of Hematology and Oncology at UT Health San Antonio.\"Dr. Taverna's research has shown that AXL and JAK-STAT3 work in tandem to transmit signals promoting tumor growth and metastasis in advanced lung cancer. We are pleased to see this research advancing into clinical application and believe this study aligns closely with BerGenBio's strategic focus on addressing the significant unmet needs of lung cancer patients, including first-line Non-Small Cell Lung Cancer patients with mutations in the STK11 g","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/bergenbio-announces-first-patient-entered-062600576.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bergenbio-announces-first-patient-entered-062600576.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AEIS","NCI","IE00B7SZL793.SGD","BRRGF","IE0031619046.USD","BK4202","BK4157","IE00B66KJ199.SGD","IE00B19Z4B17.USD","BK4139"],"gpt_icon":0},{"id":"2493237209","title":"Neo-Concept International Group Holdings First Half 2024 Earnings: EPS: HK$0.075 (vs HK$0.29 loss in 1H 2023)","url":"https://stock-news.laohu8.com/highlight/detail?id=2493237209","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493237209?lang=en_us&edition=fundamental","pubTime":"2024-12-21 20:56","pubTimestamp":1734785786,"startTime":"0","endTime":"0","summary":"Neo-Concept International Group Holdings  First Half 2024 Results. Profit margin: 1.8% . The move to profitability was primarily driven by lower expenses.NasdaqCM:NCI Earnings and Revenue History December 21st 2024. All figures shown in the chart above are for the trailing 12 month  period. We don't want to rain on the parade too much, but we did also find 3 warning signs for Neo-Concept International Group Holdings that you need to be mindful of.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neo-concept-international-group-holdings-125626676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NCI"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":110,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NCI\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NCI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NCI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NCI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NCI","date":"2025-04-17","current":5.733501,"percent":0.087336,"low":-615.963293,"twenty":6.823071,"median":16.327956,"eighty":24.52062,"high":50.080918,"avg":6.908672,"sd":53.27237,"marketCap":8128000},"quantilePoints":[{"date":"2024-04-26","current":-152.934443,"twenty":-421.533502,"median":-222.424043,"eighty":-152.416021,"marketCap":47955200},{"date":"2024-05-03","current":-75.704037,"twenty":-208.526123,"median":-121.807344,"eighty":-81.702314,"marketCap":23774400},{"date":"2024-05-10","current":-74.39805,"twenty":-152.15681,"median":-81.565326,"eighty":-71.297323,"marketCap":23368000},{"date":"2024-05-17","current":36.631419,"twenty":-133.739762,"median":-74.39805,"eighty":-23.514082,"marketCap":20726400},{"date":"2024-05-24","current":30.19238,"twenty":-105.051475,"median":-71.169081,"eighty":36.421773,"marketCap":17068800},{"date":"2024-05-31","current":28.783514,"twenty":-89.228644,"median":-65.79629,"eighty":35.854613,"marketCap":16256000},{"date":"2024-06-07","current":28.579978,"twenty":-81.702314,"median":24.992177,"eighty":34.642796,"marketCap":16154400},{"date":"2024-06-14","current":31.815689,"twenty":-79.845114,"median":25.185699,"eighty":33.392506,"marketCap":17983200},{"date":"2024-06-21","current":25.826264,"twenty":-75.704037,"median":25.951163,"eighty":31.815689,"marketCap":14610080},{"date":"2024-06-28","current":24.010495,"twenty":-75.181642,"median":25.826264,"eighty":31.166365,"marketCap":13573760},{"date":"2024-07-05","current":21.847045,"twenty":-74.134092,"median":24.992177,"eighty":30.05711,"marketCap":12350496},{"date":"2024-07-12","current":24.005484,"twenty":-72.824666,"median":24.22361,"eighty":29.406809,"marketCap":13573760},{"date":"2024-07-15","current":23.309684,"twenty":-72.571072,"median":24.010495,"eighty":29.29759,"marketCap":13183616},{"date":"2024-08-02","current":17.799213,"twenty":-72.317479,"median":24.00799,"eighty":29.18837,"marketCap":10054336},{"date":"2024-08-09","current":15.712059,"twenty":-71.040839,"median":23.456094,"eighty":28.858081,"marketCap":8900160},{"date":"2024-08-16","current":14.71315,"twenty":-69.000048,"median":23.177414,"eighty":28.661392,"marketCap":8331200},{"date":"2024-08-23","current":15.475212,"twenty":-65.359249,"median":22.360574,"eighty":28.479131,"marketCap":8761984},{"date":"2024-08-30","current":15.211668,"twenty":-16.796281,"median":21.73132,"eighty":28.375818,"marketCap":8611616},{"date":"2024-09-06","current":15.60865,"twenty":14.533412,"median":17.564477,"eighty":28.127716,"marketCap":8839200},{"date":"2024-09-13","current":18.316746,"twenty":14.714645,"median":17.091682,"eighty":27.226945,"marketCap":10363200},{"date":"2024-09-20","current":30.136472,"twenty":14.729124,"median":17.451967,"eighty":27.226945,"marketCap":17068800},{"date":"2024-09-27","current":18.155945,"twenty":14.756986,"median":17.799213,"eighty":26.316487,"marketCap":10304272},{"date":"2024-10-04","current":24.668714,"twenty":14.779837,"median":18.134605,"eighty":27.226945,"marketCap":14022832},{"date":"2024-10-11","current":19.411936,"twenty":14.800605,"median":18.316746,"eighty":26.316487,"marketCap":11029696},{"date":"2024-10-18","current":27.159393,"twenty":14.841085,"median":19.188638,"eighty":26.316487,"marketCap":15422880},{"date":"2024-10-25","current":22.801653,"twenty":14.96086,"median":20.067961,"eighty":27.538745,"marketCap":12954000},{"date":"2024-10-31","current":26.444278,"twenty":15.097424,"median":21.615595,"eighty":28.23974,"marketCap":15016480},{"date":"2024-11-08","current":25.398607,"twenty":15.188698,"median":21.880614,"eighty":27.72766,"marketCap":14427200},{"date":"2024-11-15","current":22.207911,"twenty":15.214052,"median":22.207911,"eighty":27.409251,"marketCap":12598400},{"date":"2024-11-22","current":20.742686,"twenty":15.227723,"median":22.212919,"eighty":27.092873,"marketCap":11765280},{"date":"2024-11-29","current":19.71984,"twenty":15.244259,"median":22.031838,"eighty":26.826792,"marketCap":11184128},{"date":"2024-12-06","current":19.342155,"twenty":15.419442,"median":21.847045,"eighty":26.825987,"marketCap":10972800},{"date":"2024-12-13","current":18.931587,"twenty":15.475212,"median":20.935809,"eighty":26.444278,"marketCap":10749280},{"date":"2024-12-20","current":16.81288,"twenty":15.549996,"median":20.067961,"eighty":26.379894,"marketCap":9550400},{"date":"2024-12-27","current":7.581302,"twenty":15.240125,"median":20.023482,"eighty":26.25308,"marketCap":10741152},{"date":"2025-01-03","current":8.618162,"twenty":15.140189,"median":19.71984,"eighty":26.21899,"marketCap":12196064},{"date":"2025-01-10","current":10.05795,"twenty":14.800605,"median":19.685908,"eighty":26.181452,"marketCap":14224000},{"date":"2025-01-17","current":8.786233,"twenty":14.714645,"median":19.468094,"eighty":26.125394,"marketCap":12415520},{"date":"2025-01-24","current":9.780279,"twenty":10.25185,"median":19.354401,"eighty":26.087984,"marketCap":13817600},{"date":"2025-01-31","current":8.55813,"twenty":9.931507,"median":18.990258,"eighty":25.926183,"marketCap":12088368},{"date":"2025-02-07","current":8.034161,"twenty":9.67709,"median":18.942456,"eighty":25.806345,"marketCap":11354816},{"date":"2025-02-14","current":7.429972,"twenty":9.170381,"median":18.736365,"eighty":25.661057,"marketCap":10499344},{"date":"2025-02-21","current":7.182682,"twenty":8.786233,"median":18.611629,"eighty":25.398607,"marketCap":10166096},{"date":"2025-02-28","current":6.088957,"twenty":8.49005,"median":18.298903,"eighty":25.263582,"marketCap":8617712},{"date":"2025-03-07","current":6.285152,"twenty":8.101774,"median":18.113266,"eighty":25.252549,"marketCap":8900160},{"date":"2025-03-14","current":5.596631,"twenty":7.768683,"median":17.68941,"eighty":25.185699,"marketCap":7924800},{"date":"2025-03-21","current":6.28575,"twenty":7.480228,"median":17.54621,"eighty":25.06182,"marketCap":8900160},{"date":"2025-03-28","current":6.3175,"twenty":7.319362,"median":17.202773,"eighty":24.992177,"marketCap":8940800},{"date":"2025-04-04","current":6.433722,"twenty":7.066391,"median":16.81288,"eighty":24.761928,"marketCap":9104010},{"date":"2025-04-11","current":7.43656,"twenty":6.901399,"median":16.523806,"eighty":24.668714,"marketCap":10546080},{"date":"2025-04-17","current":5.733501,"twenty":6.823071,"median":16.327956,"eighty":24.52062,"marketCap":8128000}],"updateTime":1745302428294}}}